Contents 3 min read
Claim and source comparison
Comparison scope: Kennedy 2010, Wightman 2014, Walle 2004 and Chow 2010 abstracts; Witte 2014 PMC methods and results sections. Matching, mixtures and biomarker limits were examined; not a full clinical review of all sources.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Human randomized controlled trial
Kennedy 2010: Single 250/500 mg trans-resveratrol increased some cerebral blood-flow measures in a randomized crossover trial of 22 healthy adults; cognitive performance did not change. Plasma measures involved a separate nine-person group.
A blood-flow biomarker is not memory enhancement. A single-dose task measure does not establish chronic treatment, dementia prevention or universal healthy-person benefit; the two samples are not combined.
Source 1 · Abstract read
Human controlled trial; randomization not verified
Witte et al. (2014) studied 46 adults for 26 weeks using 200 mg/day resveratrol plus 320 mg/day quercetin. Some memory and hippocampal connectivity measures improved; this does not establish that 75–150 mg resveratrol alone improves cerebral blood flow and all memory measures.
PMC methods describe 24 selected for intervention; after one exclusion, 23 were analyzed with 23 matched controls. Full randomized allocation to both groups was not verified. Mixture findings cannot be attributed to pure resveratrol or dementia prevention.
Source 2 · Full text read
Human randomized controlled trial
Wightman 2014: 23 adults received 250 mg resveratrol ±20 mg piperine in a randomized crossover comparison. The mixture increased blood flow, not cognition, mood or blood pressure. A separate six-person plasma group showed no significant bioavailability increase.
Blood-flow changes are not equivalent to plasma absorption or clinical cognitive benefit. These small, distinct samples justify neither absorption-booster advice for every product nor safe-combination claims.
Source 5 · Abstract read
Human pharmacokinetic study
Walle 2004: In six volunteers, at least 70% of 25 mg oral labeled resveratrol was absorbed; unchanged plasma resveratrol was <5 ng/mL. Measurements tracking resveratrol and metabolites together reported about 9.2 hours plasma half-life.
Absorption is not systemic bioavailability of unchanged parent compound. The duration of jointly tracked species does not validate a 1–3-hour pure-resveratrol model; 9.2 hours is not converted into a personal dose curve either.
Source 6 · Abstract read
Uncontrolled human intervention study
Chow 2010: After 42 healthy volunteers received 1 g/day resveratrol for four weeks, drug-probe indices of CYP3A4, CYP2D6 and CYP2C9 were inhibited; CYP1A2 was induced. This was an uncontrolled before/after human intervention.
Enzyme-probe changes do not prove identical drug-level increases, clinical bleeding or cancer prevention. They cannot be generalized to every product/dose or patient group and do not guarantee safety at 1–2 g/day.
Source 7 · Abstract read
Correction 2026-11-11: Blood flow was separated from memory, the matched quercetin-mixture study from pure resveratrol, and metabolite duration from parent compound. Generic dosing, the 1–3-hour model, product/wine advice and safety assurances were removed.
What is Resveratrol?
Resveratrol is a plant polyphenol. Small human studies have explored blood-flow and memory measures; human lifespan extension or established anti-aging synergy with NMN has not been demonstrated.
Clinical Trials
Kennedy 2010: Single 250/500 mg trans-resveratrol increased some cerebral blood-flow measures in a randomized crossover trial of 22 healthy adults; cognitive performance did not change. Plasma measures involved a separate nine-person group.
A blood-flow biomarker is not memory enhancement. A single-dose task measure does not establish chronic treatment, dementia prevention or universal healthy-person benefit; the two samples are not combined.
Witte et al. (2014) studied 46 adults for 26 weeks using 200 mg/day resveratrol plus 320 mg/day quercetin. Some memory and hippocampal connectivity measures improved; this does not establish that 75–150 mg resveratrol alone improves cerebral blood flow and all memory measures.
PMC methods describe 24 selected for intervention; after one exclusion, 23 were analyzed with 23 matched controls. Full randomized allocation to both groups was not verified. Mixture findings cannot be attributed to pure resveratrol or dementia prevention.
Wightman 2014: 23 adults received 250 mg resveratrol ±20 mg piperine in a randomized crossover comparison. The mixture increased blood flow, not cognition, mood or blood pressure. A separate six-person plasma group showed no significant bioavailability increase.
Blood-flow changes are not equivalent to plasma absorption or clinical cognitive benefit. These small, distinct samples justify neither absorption-booster advice for every product nor safe-combination claims.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Walle 2004: In six volunteers, at least 70% of 25 mg oral labeled resveratrol was absorbed; unchanged plasma resveratrol was <5 ng/mL. Measurements tracking resveratrol and metabolites together reported about 9.2 hours plasma half-life.
Absorption is not systemic bioavailability of unchanged parent compound. The duration of jointly tracked species does not validate a 1–3-hour pure-resveratrol model; 9.2 hours is not converted into a personal dose curve either.
Safety and Side Effects
Chow 2010: After 42 healthy volunteers received 1 g/day resveratrol for four weeks, drug-probe indices of CYP3A4, CYP2D6 and CYP2C9 were inhibited; CYP1A2 was induced. This was an uncontrolled before/after human intervention.
Enzyme-probe changes do not prove identical drug-level increases, clinical bleeding or cancer prevention. They cannot be generalized to every product/dose or patient group and do not guarantee safety at 1–2 g/day.
Resveratrol can alter drug metabolism. Human enzyme-probe findings do not establish increased bleeding with every anticoagulant; missing interaction records do not establish safety either. Do not stop medication independently; review products and medicines with the care team.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Brain Aging: Limits of Nootropic Research
NMN, resveratrol and other compounds are studied for aging mechanisms; no nootropic protocol has been established to slow cognitive decline in humans.
Sources
- Kennedy DO, et al. (2010). Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. American Journal of Clinical Nutrition, 91(6), 1590–1597. PubMed · PMID 20357044
- Witte AV, et al. (2014). Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. Journal of Neuroscience, 34(23), 7862–7870. PubMed · PMID 24899709
- Baur JA, Sinclair DA. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery, 5(6), 493–506. PubMed · PMID 16732220
- Lagouge M, et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell, 127(6), 1109–1122. PubMed · PMID 17112576
- Wightman EL, et al. (2014). Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. British Journal of Nutrition, 112(2), 203–13. https://doi.org/10.1017/S0007114514000737 PubMed · PMID 24804871
- Walle T, et al. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug metabolism and disposition: the biological fate of chemicals, 32(12), 1377-82. https://doi.org/10.1124/dmd.104.000885 PubMed · PMID 15333514
- Chow HH, et al. (2010). Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prevention Research (Philadelphia, PA), 3(9), 1168-75. https://doi.org/10.1158/1940-6207.CAPR-09-0155 PubMed · PMID 20716633
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Resveratrol is a plant polyphenol. Small human studies have explored blood-flow and memory measures; human lifespan extension or established anti-aging synergy with NMN has not been demonstrated.
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Resveratrol is a plant polyphenol. Small human studies have explored blood-flow and memory measures; human lifespan extension or established anti-aging synergy with NMN has not been demonstrated.
Study quantities are neither nutritional requirements nor effective treatment doses for everyone. These data do not recommend drinking wine or taking supplements.